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Open aAbstract The integrin αIIbβ3 plays a critical role in mediating clot retraction by
platelets which is important in vivo in consolidating thrombus formation. Actin–
myosin interaction is essential for clot retraction. In the present study, we
demonstrate that the structurally distinct Src kinase inhibitors, PP2 and PD173952,
significantly reduced the rate of clot retraction, but did not prevent it reaching
completion. This effect was accompanied by abolition of αIIbβ3-dependent protein
tyrosine phosphorylation, including PLCγ2. A role for PLCγ2 in mediating clot
retraction was demonstrated using PLCγ2-deficient murine platelets. Furthermore,
platelet adhesion to fibrinogen leads to MLC phosphorylation through a pathway that
is inhibited by PP2 and by the PLC inhibitor, U73122. These results demonstrate a
partial role for Src kinase-dependent activation of PLCγ2 and MLC phosphorylation in
mediating clot retraction downstream of integrin αIIbβ3.
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Activation of integrin αIIbβ3 by ‘inside-out’ signals
leads to binding of fibrinogen and platelet aggrega-
tion. In turn, clustering of αIIbβ3 as a consequence of
engagement of αIIbβ3 by fibrinogen mediates ‘out-
side-in’ signals that stimulate tyrosine phosphory-
lation of β3-integrin tail [1] and activation of a Src-
252 K. Suzuki-Inoue et al.based signalling cascade [2] that involves Syk [3,4],
SLP-76 [5] and PLCγ2 [6,7]. Binding of Syk to the
αIIbβ3-tail is inhibited by tyrosine phosphorylation of
the β3-integrin tail [8], suggesting that these two
integrin-dependent signalling cascades are distinct.
Activation of PLCγ2 downstream of activation of Src
kinases has been shown to be essential for platelet
spreading (lamellipodia formation) on fibrinogen
[2,6,7], whereas the role of tyrosine phosphoryla-
tion of the β3-integrin tail in this response is not
known.
It is well established that integrin αIIbβ3 plays a
critical role in regulating clot retraction by plate-
lets, which serves to consolidate thrombus forma-
tion. Clot retraction is mediated by the interaction
of fibrin and the actin cytoskeleton via integrin
αIIbβ3, together with activation of the platelet
contractile apparatus [9]. Tyrosine phosphorylation
of the β3-integrin tail has been shown to play a role
in mediating clot retraction, but is not essential.
Platelets from a mutant mouse in which the two
conserved tyrosines in the β3-integrin tail, positions
747 and 759, have been mutated to phenylalanine
(diY-F mutant) exhibit impaired clot retraction in
vitro, in line with recurrent bleeding in vivo
following tail excision [10]. Significantly, these
observations are consistent with a reported role
for tyrosine kinases in cytoskeletal attachment to
αIIbβ3 and retraction of fibrin polymers [11].
Paradoxically, however, it has been reported that
the time course of clot retraction parallels that of
protein tyrosine dephosphorylation [12]. The expla-
nation for these contrasting observations is unclear.
In the present study, we have investigated the
contribution of αIIbβ3-dependent regulation of Src
kinases and PLCγ2 in the process of clot retraction
in platelets. The results reveal a partial, but non-
essential role for Src kinases and PLCγ2 in mediating
clot retraction in platelets. The results support a
model in which outside-in signalling through integ-
rin αIIbβ3 to PLCγ2 contributes to the regulation of
the contractile apparatus that underlies clot
retraction.
Materials and methods
Antibodies and reagents
Anti-phospho-MLC monoclonal antibody (mAb) or
anti-MLC polyclonal Ab (pAb) were kindly donated
by Drs. Koichiro Fukuda and Yasuharu Sasaki
(Frontier 21 Project, Life Science Center, Asahi
Chemical, Shizuoka, Japan). PD173952 was a gift
from Pfizer (Ann Arbor, Michigan, USA) [13]. Myosin
II inhibitor, blebbistatin(-), its inactive enantiomerblebbistatin(+), Rho kinase inhibitor Y-27632, Src
kinase inhibitor PP2, and its inactive control PP3
were from Calbiochem (CA, USA). Human fibrinogen
and thrombin were obtained from Sigma (MO, USA).
Integrin αIIbβ3 blocking peptide GRGDS was from
Peptide Institute (Osaka, Japan). PLCγ2-deficient
mice were obtained as previously described [14].
Anti-PLCγ2 antibody was obtained from Santa Cruz
Biotechnology (CA, USA).
Preparation of human and mouse platelets
Venus blood from drug-free volunteers was taken
into 10% sodium citrate. Platelet-rich plasma was
obtained after centrifugation at 1100 rpm for
12 min. 15% acid–citrate–dextrose and 250 ng/ml
of prostaglandin I2 were added, and the platelet-
rich plasma (PRP) was centrifuged at 2500 rpm for
10 min. Human platelets were resuspended in
modified Tyrodes buffer (137 mM NaCl, 11.9 mM
NaHCO3, 0.4 mM Na2HPO4, 2.7 mM KCl, 1.1 mM
MgCl2, 5.6 mM glucose, pH 7.3), washed again, and
resuspended at a cell density of 5×108/ml. Murine
blood (approximately 1 ml) was drawn from CO2
terminally-narcosed mice by portal vein puncture
and taken into 100 μl of 4% sodium citrate. The
citrated blood was added to 0.7 vol. of modified
Tyrodes buffer. PRP was obtained by centrifugation
at 200g for 5 min. To obtain murine washed
platelets, murine blood was drawn into 100 μl of
acid citrate dextrose and PRP was obtained by
centrifugation at 200 g for 5 min. Plasma was
removed by centrifugation at 1000 g for 10 min in
the presence of 1 μg/ml of PGI2. In both PRP and
washed platelets, cell densities were adjusted to
3×108/ml with Tyrodes buffer.
Clot retraction assay of human and murine
platelets
For human washed platelets, clot retraction studies
were performed at 20 °C in an air incubator in an
aggregometer tube. Assays were started by adding
250 μl of 2 U/ml thrombin to 250 μl of platelets
(5×108/ml) in the presence of 2 mg/ml fibrinogen
and 2 mM CaCl2 (final concentrations: 2.5×108/ml
of platelets, 1 U/ml of thrombin, 1 mg/ml of
fibrinogen, 1 mM CaCl2). For murine diluted-PRP
(400 μl), assays were performed at 37 °C in an
aggregometer tube containing thrombin and CaCl2
to give the final concentrations: 3×108/ml of
platelets, 10 U/ml of thrombin, 2 mg/ml fibrinogen
and 2 mM CaCl2. These conditions were chosen so
that clot retraction proceeds with a similar time
course to that seen with human platelets. Where
Figure 1 The Src kinase inhibitors and αIIbβ3 blockade by
GRGDS peptide reduced time course of clot retraction and
inhibited protein tyrosine phosphorylation during clot re-
traction. (A) Human washed platelets (5×108/ml) were
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were preincubated with inhibitors or vehicle solu-
tion for 60 min at room temperature or for 10 min at
37 °C, respectively. Clot retraction was recorded by
digital camera, Cyber-shot (Sony, Tokyo, Japan) and
by measurement of the volume of clear fluid that
could be removed [10].
Platelet aggregation
Washed human platelets (5×108/ml) were preincu-
bated with 50 μM PP3, 50 μM PP2, 80 μM blebbistatin
(-), 80 μM blebbistatin(+), DMSO, or 20 μM Y-27632
for 5 min at 37 °C. Platelets were stimulated with
1 U/ml of thrombin and platelet aggregation was
monitored in an aggregometer AA100 (Kowa Co.
Ltd., Tokyo, Japan) for 5 min at 37 °C.
Western blotting and immunoprecipitation
studies
For measurement of tyrosine phosphorylation, clot
retraction was terminated by addition of 2× lysis
buffer [15]. Samples were sonicated for 3 periods of
15 s each and insoluble debris removed by centri-
fugation at 15,000 g for 10 min. PLCγ2 was
precipitated by anti-PLCγ2 antibody as described
[6,15]. Samples were also taken and solubilized by
addition of 4× SDS sample buffer for analysis of total
protein tyrosine phosphorylation. Platelet proteins
were separated by SDS-PAGE and blotted with anti-
phosphotyrosine antibody (4G10) to detect protein
tyrosine phosphorylation as described previously
[6,15].preincubated with DMSO, 50 μM PP2, 40 μM PD173952. Clot
retraction assays were started by adding 250 μl of 2 U/ml
thrombin to 250 μl of platelets in the presence of 2 mg/ml
fibrinogen and 2 mM CaCl2 (final concentrations: 2.5×10
8/ml
of platelets, 1 U/ml of thrombin, 1 mg/ml of fibrinogen, 1 mM
CaCl2). The volume of remaining fluid was measured to assay
the degree of clot retraction. The volume was expressed as
mean±SE (n=5–18 from 2–5 experiments). Results were
analyzed using unpaired Student's t-test. One asterisk
denotes pb0.05 and two denote pb0.005 between control
and PP2/PD173952. (B) Human washed platelets in the
presence or absence of 1 mM GRGDS peptide were stimulated
by 250 μl of 2 U/ml thrombin as described. Reactions were
terminated by addition of 2× lysis buffer. Samples were
sonicated 3 periods of 15 s and insoluble debris removed by
centrifugation at 15,000 g for 10 min. The supernatant was
solubilized by addition of 4× SDS sample buffer. The platelet
proteins were separated by SDS-PAGE and blotted with anti-
phosphotyrosine antibody (4G10). (C) Human washed plate-
lets (5×108/ml) were preincubated with 50 μM PP3 or PP2
before starting assays of clot retraction. Protein tyrosine
phosphorylation was analyzed as described above.MLC phosphorylation during platelet
spreading on fibrinogen-coated surfaces
Plastic dishes for cell culture (6 cm) were coated
with 0.5 ml fibrinogen (500 μg/ml) overnight at
4 °C. After removing unbound fibrinogen, dishes
were washed with phosphate-buffered saline and
blocked with 1% BSA for 2 h at room temperature.
Human or murine washed platelets (0.4 ml at
3×108/ml), pretreated with 10 μM indomethacin
and 3 U/ml of apyrase, were seeded on BSA- or
fibrinogen-coated surfaces in the presence of the
inhibitors. Bound and unbound platelets were
solubilized by 4× Laemmli sample buffer, followed
by immediate sonication for three periods of 15 s.
Platelet proteins were separated by SDS-PAGE on
15% gels and electrotransferred. Phospho-MLC or
total MLC were blotted using anti-phospho-MLC mAb
or anti-MLC pAb [16].
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The data are expressed as the mean±SE. Data were
analyzed with a one or two-tailed, non-parametric
Mann–Whitney U-test. p value less than 0.05 was
considered statistically significant.
Results
Critical role of Src kinases in supporting clot
retraction
Clot retraction was analyzed in washed platelets in
the presence of fibrinogen (1 mg/ml) and thrombin
(1 unit/ml) by measuring the volume of fluid that
could be withdrawn from the platelet suspension.Experiments were carried out at 20 °C to reduce the
time course of response. Clot retraction increased
steadily up to 120min, at which time between 80 and
90% of the original suspension could be recovered
(Fig. 1A). Clot retraction was slowed in the presence
of concentrations of the structurally distinct Src
kinase inhibitors, PP2 and PD173952, which are
known to cause maximal inhibition of Src kinase in
platelets (Fig. 1A) [14,17,18]. The response recov-
ered towithin 20% of the control by 120min (Fig. 1A).
These results demonstrate a contributory but not
essential role for Src kinases in clot retraction.
The time course of protein tyrosine phosphorylation
during clot retractionwas analyzed.Amarked increase
in tyrosine phosphorylation of several proteins in the
whole cell lysate was observed which was maintained
for up to 120 min (Fig 1B). The apparent contradiction
with a recent report of transient phosphorylation
during clot retraction [12] may reflect the lower
temperature used in the present study. Tyrosine
phosphorylation was markedly inhibited in the pres-
ence of the αIIbβ3-blocking peptide, GRGDS (Fig. 1B)
and the structurally distinct Src kinase inhibitors, PP2
(Fig. 1C) and PD173952 (not shown), but not by the
inactive analogue of PP2, PP3 (Fig. 1C). These results
illustrate that the major increase in tyrosine phos-
phorylation is mediated downstream of αIIbβ3-depen-
dent activation of a Src kinase-dependent pathway,
consistent with previous reports [2].
PLCγ2 contributes to clot retraction
Adhesion of platelets to a fibrinogen monolayer
induces tyrosine phosphorylation of PLCγ2 through aFigure 2 A role for PLCγ2 in clot retraction. (A) Human
washed platelets (5×108/ml) were preincubated with 50 μM
PP3 or PP2 before starting assays of clot retraction. Clot
retraction was stimulated as described in the legend of Fig. 1
and reactions were terminated by addition of 2× lysis buffer.
Samples were sonicated 3 periods of 15 s and insoluble debris
removed by centrifugation at 15,000 g for 10 min. PLCγ2 was
immunoprecipitated using the supernatant. The immunopre-
cipitates were separated by SDS-PAGE and blotted with anti-
phosphotyrosine antibody (4G10) or anti-PLCγ2. (B, C) Murine
diluted-PRP (400 μl, 3×108/ml) from wild type mice or
PLCγ2-deficient mice was added 10 U/ml of thrombin and
2 mM CaCl2. Where indicated, PLCγ2-deficient platelets were
preincubated with 40 μM PD173952 before starting clot
retraction assay. Clot retraction was recorded by digital
camera (B) and the volume of remaining fluid was measured
at 120 min to assay the degree of clot retraction (C). The
results were shown as a percentage of fluid that could be
removed. The percentage of fluid was expressed as mean±SE
(n=6–9 from 3 experiments). Data were analyzed with a one-
tailed Mann–Whitney U-test. P value less than 0.05 was
considered statistically significant.
Figure 3 Myosin inhibitor, blebbistatin(-) and Rho kinase
inhibitor, Y-27632 inhibited clot retraction. Human washed
platelets (5×108/ml) were preincubated with 80 μM blebbis-
tatin(-), 80 μM blebbistatin(+) (A), DMSO, or 20 μM Y-27632
(B). Clot retraction assays were started by adding 250 μl of
2 U/ml thrombin to 250 μl of platelets in the presence of
2 mg/ml fibrinogen and 2 mM CaCl2 (final concentrations:
2.5×108/ml of platelets, 1 U/ml of thrombin, 1 mg/ml of
fibrinogen, 1 mM CaCl2). The volume of remaining fluid was
measured to assay the degree of clot retraction. The volume
was expressed as mean±SE (n=4–7 from 2 experiments).
Results were analyzed using unpaired Student's t-test. One
asterisk denotes pb0.05 and two denote pb0.005 between
the controls and the inhibitors.
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with this, thrombin stimulated a marked increase
in tyrosine phosphorylation of PLCγ2, which was
dependent on engagement of integrin αIIbβ3 as
demonstrated using the αIIbβ3 antagonist, GRGDS
peptide (not shown). Tyrosine phosphorylation of
PLCγ2 declined slightly by 120 min and was
inhibited in the presence of PP2 (Fig. 2A).
The role of PLCγ2 in the process of clot retraction
was investigated using PLCγ2-deficient murine
platelets. Conditions were chosen such that throm-
bin stimulated a similar time course of clot
retraction in mouse platelet-rich plasma to that
seen in human platelets. Clot retraction was
detectable by 30 min and increased steadily up to
120 min, at which time approximately 80% of the
original suspension could be recovered as clear fluid(Fig. 2B). The degree of clot retraction was reduced
by approximately 15% in the absence of PLCγ2
(p=0.0028; Fig. 2C). Interestingly, the degree of
clot retraction was further reduced by over 25%
when PLCγ2-deficient platelets were pretreated
with Src kinase inhibitor PD173952, which is freely
available in plasma [13] (Fig. 2C). This level of
inhibition was significantly greater than that seen in
the absence of PLCγ2 (p=0.033), but was not
significantly different from that induced by
PD173952 on its own (data not shown). This
indicates the presence of an additional Src kinase-
dependent mechanism of clot retraction, which
could be mediated, for example, through activation
of PLCγ1 [14] or downstream of tyrosine phosphor-
ylation of the integrin β3-tail [19]. These results
therefore show that, under these conditions, the
role of Src kinases in clot retraction is mediated in
part through inhibition of PLCγ2.Regulation of MLC phosphorylation events in
supporting clot retraction
It is well established that actin–myosin contraction
plays an essential role in mediating clot retraction.
In line with this, clot retraction in human platelets
was inhibited completely in the presence of a
selective inhibitor of nonmuscle myosin II, blebbis-
tatin(-) [20] (Fig. 3A), whereas the inactive enan-
tiomer blebbistatin(+) had no effect on clot
retraction (Fig. 3A). Blebbistatin(-) had no effect
on thrombin-induced platelet aggregation (not
shown), illustrating that its inhibitory effect was
not due to inhibition of binside-outQ activation of
αIIbβ3.
Actin–myosin cross-bridge formation is regulated
by phosphorylation of MLC, which can be brought
about by Ca2+-dependent activation of MLC kinase
and through Rho kinase-dependent inhibition of MLC
phosphatase. Thrombin regulates both of these
pathways through activation of PAR1 and PAR4
receptors, each of which couple to Gq and G12/13
heterotrimeric G proteins [21]. A role for Rho kinase
in mediating clot retraction is illustrated by the
partial inhibition of response in the presence of the
Rho kinase inhibitor, Y-27632, which reduced clot
retraction by 30–40% at 120 min (Fig. 3B). In
comparison, the same concentration of Y-27632
had no effect on aggregation (not shown), demon-
strating that this effect was not mediated by
inhibition of thrombin-induced activation of αIIbβ3.
A previous report that inhibition of Rho by C3-
exozyme has no effect on clot retraction [22], may
reflect the incomplete inhibition of Rho activity
that was observed in this study.
Figure 4 αIIbβ3 outside-in regulation of MLC phosphoryla-
tion was inhibited by Src inhibitor or PLC inhibitor. 0.4 ml of
human washed platelets at 3×108/ml pretreated with 10 μM
indomethacin and 3 U/ml of apyrase followed by being
incubated without (A) or with 50 μM PP2, PP3 (B), 10 μM
U73122, or U73323 (C), and then they were seeded on the
surfaces coated with BSA or fibrinogen (fib) for indicated
times. Bound and unbound platelets were solubilized by 4×
Laemmli sample buffer, followed by immediate sonication for
three periods of 5 s. Platelet proteins were separated by SDS-
PAGE on 15% gels, electrotransferred, and then phospho-MLC
or total MLC were blotted using anti-phospho-MLC mAb or
anti-MLC pAb. (D) 0.4 ml of washed platelets at 3×108/ml
from PLCγ2+/+ and PLCγ2-/- mice were pretreated with
10 μM indomethacin and 3 U/ml of apyrase and then they
were seeded on the surfaces coated with BSA or fibrinogen
(fib) for indicated times. The following procedure is the same
as that for human platelets. The data are representatives of
at least two experiments.
256 K. Suzuki-Inoue et al.Potentially, clot retraction could also be regulated
through activation of PLCβ by thrombin and/or PLCγ2
by αIIbβ3, thereby leading to Ca2+ elevation and
activation of MLC kinase. In consideration of this, we
investigated whether outside-in signals by αIIbβ3
activate MLC phosphorylation in the absence of
thrombin. To address this, we seeded washed,
human platelets on a fibrinogen-coated surface in
the absence of thrombin. Indomethacin and apyrase
were included in these studies to prevent stimulation
of phosphorylation through release of thromboxane
A2 and ADP. Immobilized fibrinogen stimulated weak
MLC phosphorylation (Fig. 4A), which was inhibited in
the presence of the Src kinase inhibitors, PP2 (Fig. 4B)
and PD173952 (not shown), and by the phospholipase
inhibitor, U73122 (Fig. 4C). The inactive enantiomers
of PP2 and U73122, namely PP3 and U73323
respectively, had no effect (Fig. 4B and C). Moreover,
MLC phosphorylation in platelets seeded on immobi-
lized fibrinogen is inhibited in PLCγ2-deficient mice
(Fig. 4D). These findings confirm that αIIbβ3 stimu-
lates MLC phosphorylation through a pathway that is
partially dependent on Src kinases and PLCγ2.Discussion
The present study demonstrates that αIIbβ3 outside-
in signalling is required for optimal clot retraction in
thrombin-stimulated platelets through a pathway
that is partially dependent on Src kinases and
PLCγ2. Significantly, however, this αIIbβ3-regulated
cascade is not essential for completion of clot
retraction, most likely because clot retraction is
regulated through a number of additional pathways,
including activation of PLCβ and Rho kinase, and
αIIbβ3-regulation of PLCγ1, which is expressed in
low level in mouse platelets [14]. A schematic
summarizing these results is shown in Fig. 5. As
expected, however, clot retraction is absolutely
dependent on myosin contractility, as demonstrated
using the inhibitor of myosin II, blebbistatin. The
present results therefore indicate that clot retrac-
tion in thrombin-stimulated platelets is regulated
through multiple pathways, including thrombin-
dependent activation of PLCβ and Rho kinase,
which activate MLC kinase and inhibit MLC phos-
phatase, respectively, and αIIbβ3-regulation of
PLCγ2, mediated downstream of Src kinase activa-
tion (Fig. 5).
A role for αIIbβ3 outside-in signalling via PLCγ2 in
clot retraction should be considered in the context
of a previous study on a mutant mouse in which the
two conserved tyrosines in the β3-integrin tail, at
positions 747 and 759, were mutated to phenylal-
anine residues. Significantly, dual mutation of these
Figure 5 Multiple mechanisms of regulation of the contractile apparatus underlie clot retraction. Thrombin receptors are
able to regulate clot retraction through activation of PLCβ and Rho kinase. αIIbβ3 outside-in signalling is required for optimal
clot retraction through bifurcating signals, namely activation of PLCγ2 and phosphorylation of the diY motif, which combine to
mediate clot retraction. This interaction could occur by recruitment of myosin to the phosphorylated diY motif in combination
of activation of MLC kinase downstream of PLCγ2.
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retraction, the importance of which is illustrated by
an increase in rebleeding following incision of the
tail [10]. Phosphorylation of tyrosine 747 and 759 in
the β3 tail is also blocked by inhibition of Src kinase
activation [19], but is independent of activation of
PLCγ2 by Syk as demonstrated using Syk-deficient
murine platelets (Hughes, Hughan and Watson,
unpublished observation). These results therefore
suggest a model in which bifurcating signals from
αIIbβ3, namely activation of PLCγ2 and phosphory-
lation of the diY motif, combine to mediate clot
retraction. This interaction could occur, for exam-
ple, by recruitment of myosin to the phosphorylated
diY motif in combination of activation of MLC kinase
downstream of PLCγ2 [23] (Fig. 5). The observation
that an increased inhibition of clot retraction is seen
in the presence of the Src kinase inhibitor PD173952
relative to that observed in the absence of PLCγ2 is
consistent with this possibility, although the differ-
ence could also be due to the presence of PLCγ1 in
murine platelets [14].
The demonstration of the presence of multiple
routes of clot retraction in platelets is consistent
with the physiological importance of this phenom-
enon. Multiple routes of regulation of MLC phos-phorylation may have evolved to ensure rapid
activation of clot retraction at sites of damage to
the vasculature in order to withstand the high shear
forces found within small arteries and arterioles.
The physiological importance of outside-in signal-
ling by αIIbβ3 in clot retraction is illustrated by the
rebleeding that occurs in the Di-YF mouse [10]. The
present results imply a significant contribution of
Src kinase-dependent regulation of PLCγ2 down-
stream of αIIbβ3 in this process (Fig. 5).
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